Search clinical trials for: Bicalutamide and CP-675,206 (Tremelimumab)

Total 1022 results

AstraZeneca

Recruiting

Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma (TREMENDOUS)

Hepatocellular Carcinoma

China
Gruppo Oncologico del Nord-Ovest

Recruiting

TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (INFINITY)

Gastric Cancer | Microsatellite Instability

Italy
Canadian Cancer Trials Group
AstraZeneca

Active, not recruiting

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

Canada
Grupo Espanol de Tumores Neuroendocrinos
MFAR

Active, not recruiting

Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY)

Metastatic Thyroid Cancer | Metastatic Thyroid Papillary Carcinoma | Metastatic Thyroid Follicular Carcinoma

Spain
Fujian Cancer Hospital

Enrolling by invitation

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Malignant Melanomas

China
Centre hospitalier de l'Université de Montréal...
AstraZeneca

Active, not recruiting

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

Head and Neck Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma

Canada
AIO-Studien-gGmbH
AstraZeneca

Completed

Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma (MEDISARC)

Recurrent Adult Soft Tissue Sarcoma | Metastatic Adult Soft Tissue Sarcoma

Germany
Kyoto Breast Cancer Research Network

Terminated

Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

Breast Cancer

Japan
Pfizer

Completed

A Study Of CP-690,550 In Stable Kidney Transplant Patients

Kidney Transplant

United States
Seoul National University Hospital
Chungnam National University Hospital; Korean Cancer Study Group

Completed

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

Head and Neck Neoplasms | HNSCC

Korea, Republic of
M.D. Anderson Cancer Center
MedImmune LLC

Active, not recruiting

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Advanced and/or Metastatic Sarcoma

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...
AstraZeneca

Terminated

Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors (APACHE)

Germ Cell Tumor

Italy
Enrico De Toni

Recruiting

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients (MONTBLANC)

Hepatocellular Carcinoma

Germany
MedImmune LLC

Terminated

A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (MEDI6469)

Advanced Solid Tumors | Aggressive B-cell Lymphomas

United States
Yale University
AstraZeneca

Withdrawn

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Malignant Melanoma
UNICANCER
Cancer Research UK; National Cancer Institute, France; Servier; Pierre Fabre Medicament and other collaborators

Recruiting

Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10)

Biliary Tract Neoplasms

France, Belgium, United Kingdom
Pfizer

Completed

A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis

Psoriasis

Japan
ARCAGY/ GINECO GROUP
AstraZeneca

Active, not recruiting

Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer (INeOV)

Ovarian Cancer

France
Cliniques universitaires Saint-Luc- Université...

Terminated

A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma

Head and Neck Cancer

Belgium
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Pfizer

Completed

Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States, Canada
Pfizer

Completed

Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug

Obesity

United States
Abramson Cancer Center at Penn Medicine

Completed

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Melanoma | Breast Cancer | Pancreatic Cancer | Metastatic | Non Small Cell Lung Cancer (NSCLC)

United States
Spanish Oncology Genito-Urinary Group
AstraZeneca; MFAR

Active, not recruiting

Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach (IMMUNOPRESERVE)

Invasive Bladder Cancer

Spain
University College, London
AstraZeneca; Cancer Research UK; Kidney Cancer UK

Recruiting

Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)

Renal Cell Carcinoma

United Kingdom
Memorial Sloan Kettering Cancer Center

Completed

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Endometrial Cancer | Endometrial Carcinoma | Endometrial Carcinosarcoma | Endometrial Cancer Recurrent | Endometrial Carcinoma, Recurrent

United States
Gustave Roussy, Cancer Campus, Grand Paris

Withdrawn

Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors (MATILDA)

Metastatic Colorectal Cancer | Triple Negative Breast Cancer | Esophageal Adenocarcinoma | Prostate Adenocarcinoma | Stomach Adenocarcinoma
Canadian Cancer Trials Group
AstraZeneca

Active, not recruiting

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Advanced Rare Tumours

Canada
European Organisation for Research and Treatment...

Withdrawn

Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) (SOLUTION)

Squamous Non-small Cell Lung Cancer | Non-Squamous Non-small Cell Lung Cancer
CHU de Quebec-Universite Laval
Cancer Research Society

Withdrawn

A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer. (CANUCK-01)

Metastatic Urothelial Carcinoma

Canada
Pfizer

Completed

Study Examing The Effect of Grapefruit Juice On The Blood And Urine Samples of Study Drug And Its By Product And Safety

Obesity

United States
AstraZeneca

Recruiting

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) (SIERRA)

Advanced Hepatocellular Carcinoma

Korea, Republic of, Italy, Spain, Vietnam, Germany, France, Japan, United States, Hong Kong, Singapore
AstraZeneca

Approved for marketing

Himalaya Early Access Program

Unresectable Hepatocellular Carcinoma

United States
Tianjin Medical University Cancer Institute and...

Recruiting

HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

Unrescetable Hepatocellular Carcinoma

China
Pfizer

Completed

A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Canada, Germany, Colombia, Hungary, Japan, Mexico, Poland, Serbia, Taiwan, Ukraine
Pfizer

Completed

A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers

Healthy

Singapore
University of Colorado, Denver
AstraZeneca

Withdrawn

Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

Colorectal Cancer
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NCIC Clinical Trials Group

Completed

Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer

Prostate Cancer

Canada
Swiss Group for Clinical Cancer Research

Completed

Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer

Prostate Cancer

Switzerland
The University of Hong Kong

Recruiting

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

HCC

Hong Kong
Gustave Roussy, Cancer Campus, Grand Paris

Active, not recruiting

A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer (ABIMMUNE)

Lung Cancer | Head and Neck Squamous Cell Carcinoma | Oesophageal Cancer

France
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Melanoma | Breast Cancer | Colorectal Cancer | Pancreatic Adenocarcinoma | Lung Cancer | Head and Neck Carcinoma | Biliary Tract Cancer | Gastroesophageal Cancer

United States
Pfizer

Terminated

A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression

Major Depressive Disorder

United States
Clavis Pharma

Completed

A Study of CP-4126 in Patients With Advanced Pancreatic Cancer

Advanced Adenocarcinoma of Pancreas

Norway, Belgium
University of Kansas Medical Center

Completed

Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

Prostate Cancer

United States
University Health Network, Toronto
Clinica Universidad de Navarra, Universidad de Navarra; University of Milan

Recruiting

Durvalumab and Tremelimumab in Resectable HCC ((NEOTOMA))

Hepatocellular Carcinoma

Spain, Canada, Italy
Memorial Sloan Kettering Cancer Center
AstraZeneca

Active, not recruiting

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Nonseminomatous Germ Cell Tumor | Seminoma | Germ Cell Tumor | Dysgerminoma | Pineal Germ Cell Tumor | Germinomatous Germ Cell Tumor

United States
GlaxoSmithKline

Completed

Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy

Neoplasms, Prostate

United States, Canada
Ocera Therapeutics

Terminated

Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI

Gastroesophageal Reflux Disease (GERD)

United States
Pfizer

Terminated

Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

Sarcoma | Breast Neoplasms | Lung Neoplasms | Prostatic Neoplasms | Colorectal Neoplasms

United States, Finland, Canada, Germany

Search clinical trials for: Bicalutamide and CP-675,206 (Tremelimumab)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations